BR112020005460A8 - Preparação de formas de dosagem sólidas compreendendo anticorpos por estratificação em solução/suspensão - Google Patents

Preparação de formas de dosagem sólidas compreendendo anticorpos por estratificação em solução/suspensão

Info

Publication number
BR112020005460A8
BR112020005460A8 BR112020005460A BR112020005460A BR112020005460A8 BR 112020005460 A8 BR112020005460 A8 BR 112020005460A8 BR 112020005460 A BR112020005460 A BR 112020005460A BR 112020005460 A BR112020005460 A BR 112020005460A BR 112020005460 A8 BR112020005460 A8 BR 112020005460A8
Authority
BR
Brazil
Prior art keywords
dosage forms
solid dosage
antibodies
solution
suspension
Prior art date
Application number
BR112020005460A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112020005460A2 (pt
Inventor
Varum Felipe
Von Rochow Laetitia
Götz Carmen
Bravo Roberto
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020005460(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of BR112020005460A2 publication Critical patent/BR112020005460A2/pt
Publication of BR112020005460A8 publication Critical patent/BR112020005460A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020005460A 2017-09-20 2018-09-11 Preparação de formas de dosagem sólidas compreendendo anticorpos por estratificação em solução/suspensão BR112020005460A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192260.2A EP3459528B1 (en) 2017-09-20 2017-09-20 Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP17192260.2 2017-09-20
PCT/EP2018/074520 WO2019057562A1 (en) 2017-09-20 2018-09-11 PREPARATION OF SOLID GALENIC SHAPES COMPRISING ANTIBODIES BY SOLUTION / SUSPENSION STRATIFICATION

Publications (2)

Publication Number Publication Date
BR112020005460A2 BR112020005460A2 (pt) 2020-09-24
BR112020005460A8 true BR112020005460A8 (pt) 2022-12-27

Family

ID=59923358

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020005460A BR112020005460A8 (pt) 2017-09-20 2018-09-11 Preparação de formas de dosagem sólidas compreendendo anticorpos por estratificação em solução/suspensão

Country Status (27)

Country Link
US (2) US11826470B2 (enExample)
EP (2) EP3459528B1 (enExample)
JP (2) JP7204743B2 (enExample)
KR (2) KR20200055711A (enExample)
CN (1) CN111093635A (enExample)
AR (1) AR112901A1 (enExample)
AU (2) AU2018337493B2 (enExample)
BR (1) BR112020005460A8 (enExample)
CA (1) CA3075862A1 (enExample)
CL (1) CL2020000735A1 (enExample)
CO (1) CO2020003070A2 (enExample)
CR (2) CR20210203A (enExample)
EA (1) EA202090640A8 (enExample)
ES (1) ES2938609T3 (enExample)
GE (2) GEP20227351B (enExample)
IL (2) IL272933B2 (enExample)
JO (1) JOP20200064A1 (enExample)
MA (1) MA50157A (enExample)
MX (1) MX2020003032A (enExample)
MY (1) MY209948A (enExample)
PH (1) PH12020500353A1 (enExample)
SA (1) SA520411573B1 (enExample)
SG (1) SG11202002203YA (enExample)
TW (1) TWI802592B (enExample)
UA (1) UA129148C2 (enExample)
WO (1) WO2019057562A1 (enExample)
ZA (2) ZA202001752B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
CN112263564B (zh) * 2020-10-30 2022-07-19 黄山中皇制药有限公司 一种喜炎平干混悬剂的制备方法
CN112107694B (zh) * 2020-10-30 2022-07-22 黄山中皇制药有限公司 一种喜炎平干混悬剂
CN116236463A (zh) * 2023-02-16 2023-06-09 山东省药学科学院 右酮洛芬缓释微丸胶囊及其制备方法
CN120981225A (zh) 2023-03-28 2025-11-18 蒂洛特斯制药股份有限公司 用于在下部胃肠道中缓释的包含抗体的固体口服剂型

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
EP0725789B1 (en) 1993-09-20 2003-03-19 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO2000018500A1 (de) 1998-09-24 2000-04-06 Glatt Systemtechnik Dresden Gmbh Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung
CZ302332B6 (cs) 1997-12-20 2011-03-16 Genencor International, Inc. Vrstvená granule s jedinou základní cásticí
US6074689A (en) * 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
CA2566311A1 (en) 2004-05-19 2005-12-08 Glatt Air Techniques, Inc. Micropellet containing pellets and method of preparing such pellets
WO2006102964A2 (en) 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
US20080152719A1 (en) * 2005-03-29 2008-06-26 Roehm Gmbh Multiparticulate Pharmaceutical Form Comprising Pellets With a Matrix Which Influences the Delivery of a Modulatory Substance
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
BRPI0707616A2 (pt) 2006-02-09 2011-05-10 Alba Therapuetics Corp formulaÇÕes para um efetor de junÇço oclusiva
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JPWO2008117814A1 (ja) 2007-03-26 2010-07-15 帝國製薬株式会社 大腸送達用経口製剤
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
KR20100101106A (ko) 2008-01-03 2010-09-16 애보트 프러덕츠 게엠베하 정제 미생물 리파제 과립들을 포함하는 약학 조성물 및 소화 장애들의 예방 또는 치료방법
LT3444274T (lt) 2008-06-25 2021-03-25 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys tnf
BRPI0914663A2 (pt) 2008-06-25 2015-10-20 Esbatech Alcon Biomed Res Unit humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
CN104800147A (zh) 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 用于大分子的增强的递送的方法和组合物
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
DK3272342T3 (da) * 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
DK2691415T3 (en) * 2011-03-28 2018-10-29 Ablynx Nv PROCEDURE FOR PREPARING SOLID FORMULATIONS CONTAINING VARIABLE SINGLE DOMAINS OF IMMUNOGLOBULIN
WO2014142938A1 (en) 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering

Also Published As

Publication number Publication date
IL318231A (en) 2025-03-01
TWI802592B (zh) 2023-05-21
ZA202210822B (en) 2024-10-30
UA129148C2 (uk) 2025-01-29
GEP20227351B (en) 2022-02-10
EP3684339A1 (en) 2020-07-29
TW201914578A (zh) 2019-04-16
SG11202002203YA (en) 2020-04-29
MX2020003032A (es) 2020-07-22
US20240099980A1 (en) 2024-03-28
CL2020000735A1 (es) 2020-10-23
JP2020534290A (ja) 2020-11-26
AR112901A1 (es) 2019-12-26
JOP20200064A1 (ar) 2020-03-17
CA3075862A1 (en) 2019-03-28
AU2024219328A1 (en) 2024-09-19
IL272933A (en) 2020-04-30
PH12020500353A1 (en) 2021-01-25
MA50157A (fr) 2020-07-29
GEP20237504B (en) 2023-04-25
CN111093635A (zh) 2020-05-01
IL272933B1 (en) 2025-02-01
IL272933B2 (en) 2025-06-01
ES2938609T3 (es) 2023-04-13
KR20240137117A (ko) 2024-09-19
JP7204743B2 (ja) 2023-01-16
MY209948A (en) 2025-08-14
US11826470B2 (en) 2023-11-28
EP3459528A1 (en) 2019-03-27
SA520411573B1 (ar) 2023-12-19
US20210030682A1 (en) 2021-02-04
KR20200055711A (ko) 2020-05-21
EA202090640A1 (ru) 2020-06-15
AU2018337493B2 (en) 2024-09-12
ZA202001752B (en) 2025-04-30
WO2019057562A1 (en) 2019-03-28
CR20200130A (es) 2020-08-06
EA202090640A8 (ru) 2021-12-28
JP2023036901A (ja) 2023-03-14
BR112020005460A2 (pt) 2020-09-24
AU2018337493A1 (en) 2020-03-19
CR20210203A (es) 2022-03-21
CO2020003070A2 (es) 2020-04-13
EP3459528B1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
BR112020005460A8 (pt) Preparação de formas de dosagem sólidas compreendendo anticorpos por estratificação em solução/suspensão
CL2019000643A1 (es) Anticuerpos de unión a cd3.
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
BR112012015147A2 (pt) conjugado de complexo de agente e pelo menos um ligante localizador de alvo, análogo de prostaciclina, e, composição terapêutica para o tratamento de distúrbios pulmonares
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EP4338803A3 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EA202091478A1 (ru) Антитела
EA202091482A1 (ru) Антитела
WO2018111670A3 (en) Antibodies to human alpha-synuclein
MX2016011045A (es) Terapia de combinacion para cancer.
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
WO2016020880A3 (en) Angiopoietin-like 4 antibodies and methods of use
BR112019027348A2 (pt) nanopartículas de albumina para tratamento de câncer e doenças oculares
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
AR112701A1 (es) Método para preparar una forma de dosificación sólida que comprende anticuerpos por granulación en húmedo, extrusión y esferonización
WO2013090965A3 (de) Zusammensetzung enthaltend antikörper gegen gluten und gerbstoffe

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]